Losartan/Hydrochlorothiazide
Brand name: Losartan-Hydrochlorothiazide
Rank #265 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$46.3M
Total Cost
2,039,676
Total Claims
$46.3M
Total Cost
54,866
Prescribers
$23
Cost per Claim
414,538
Beneficiaries
5,316,181
30-Day Fills
$843
Avg Cost/Provider
37
Avg Claims/Provider
Share of Medicare Part D Spending
0.02%
of total Medicare Part D spending
$46.3M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $46.3M total
Top Prescribers of Losartan/Hydrochlorothiazide
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Mohammad Chaudhry | Internal Medicine | Union City, NJ | 1,441 | $60K |
| 2 | Paramjit Takhar | Family Practice | Sacramento, CA | 1,283 | $36K |
| 3 | Alberto Rozo | Internal Medicine | Jackson Heights, NY | 588 | $35K |
| 4 | Michael Correa | Internal Medicine | New York, NY | 573 | $34K |
| 5 | Xueshu Zhang | Internal Medicine | Flushing, NY | 1,360 | $28K |
| 6 | Dae Rheem | Gastroenterology | Los Angeles, CA | 1,748 | $26K |
| 7 | Anthony Jung | Internal Medicine | Flushing, NY | 1,320 | $25K |
| 8 | Rafael Rodriguez | Internal Medicine | Jackson Heights, NY | 373 | $23K |
| 9 | Enrique Griego | Family Practice | Mcallen, TX | 613 | $22K |
| 10 | Ajith Karayil | Family Practice | Bronx, NY | 419 | $22K |
| 11 | Jose Rivera | Cardiology | Arecibo, PR | 980 | $22K |
| 12 | Mark Song | Internal Medicine | Los Angeles, CA | 899 | $22K |
| 13 | Min Wong | Internal Medicine | Brooklyn, NY | 530 | $22K |
| 14 | Alvaro Ramirez | Family Practice | Jackson Heights, NY | 392 | $21K |
| 15 | Tung Nguyen | Family Practice | San Jose, CA | 660 | $21K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 262 | Clozapine (Clozapine) | $47.0M | 491,951 |
| 263 | Pembrolizumab (Keytruda) | $46.9M | 3,947 |
| 264 | Glipizide (Glipizide) | $46.9M | 2,961,035 |
| 265 | Losartan/Hydrochlorothiazide (Losartan-Hydrochlorothiazide) | $46.3M | 2,039,676 |
| 266 | Darunavir (Prezista) | $46.0M | 21,793 |
| 267 | C1 Esterase Inhibitor (Haegarda) | $45.8M | 894 |
| 268 | Alectinib Hcl (Alecensa) | $45.7M | 2,686 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology